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Abstract
Background: The recurrent Guillain-Barré syndrome (RGBS) is characterized by at least two GBS episodes with
intervening remission. In a previous study of monophasic GBS, we reported that the magnitude of oxygen radical
production ("respiratory burst”) in peripheral blood leukocytes was inversely correlated to disease severity. The
present study sought to establish a similar correlation in patients with RGBS.
Methods: Oxygen radical production in leukocytes was induced by formyl-Met-Leu-Phe (fMLF), Trp-Lys-Tyr-Met-Val-
Met-NH2 (WKYMVM), or phorbol myristate acetate (PMA) and assessed by quantifying superoxide anion formed by
the leukocyte NADPH oxidase.
Results: Disease severity, assessed using the MRC score, was negatively correlated to superoxide anion production
triggered by fMLF or WKYMVM (p = 0.001 and 0.002, respectively; n = 10). Superoxide anion production also was
significantly lower in RGBS patients with incomplete recovery after stimulation with fMLF (p = 0.004) or WKYMVM
(p = 0.003).
Conclusion: We conclude that a lower respiratory burst in leukocytes is strongly associated with a severe course of
RGBS.
Introduction
The recurrent Guillain-Barré syndrome (RGBS) is a
demyelinating disease of the peripheral nervous system
characterized by episodes of relapsing and remitting
symptoms with complete or near complete functional
recovery between episodes [1-3]. Each episode fulfils the
diagnostic criteria for GBS including symmetric limb
weakness and decreased or absent muscle reflexes, or
Miller Fisher syndrome [4,5].
The respiratory burst in human phagocytes is a pivotal
anti-microbial effector function of the innate immune
defense [6]. The nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase initiates the respiratory
burst by reducing oxygen in phagocytic cells to form
reactive oxygen species such as superoxide anions,
hydrogen peroxide, toxic halids, and hydroxyl radicals.
While it is well established that these toxic oxygen deri-
vatives participate in controlling bacterial and parasitic
infections, a deficiency in NADPH oxidase activity may
also be related to the development of autoimmunity. A
polymorphism in Ncf1, which encodes a cytosolic oxi-
dase component, compromises NADPH oxidase func-
tion and predisposes for a severe course of experimental
autoimmune encephalitis, arthritis, and neuritis in
rodent models [7-9].
In patients with the monophasic form of GBS, a low
capacity of blood leukocytes to generate oxygen radicals
in response to stimulation with NADPH oxidase-activat-
ing agents was recently found to correlate with a severe
course of disease [10]. A similar correlation has also
been found in multiple sclerosis [11]. The present study
was designed to determine a putative relationship
between the intensity of respiratory burst in leukocytes
and disease severity in patients with RGBS.
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Trp-Lys-Tyr-Met-Val-Met-NH2 (WKYMVM) was from
Alta Bioscience (University of Birmingham, United
Kingdom). N-formyl-Met-Leu-Phe (fMLF) and phorbol
myristate acetate (PMA) were from Sigma Chemical Co.
(St. Louis, Missouri). Horseradish peroxidase (HRP) was
from Boehringer-Mannheim (Mannheim, Germany).
Luminol and isoluminol were from Sigma Chemical Co.
Study subjects and diagnostic criteria
RGBS patients were included according to the following
definition: at least two episodes of relapsing symmetric
limb weakness with decreased or absent muscle reflexes,
where each episode fulfilled the diagnostic criteria for GBS
with time from onset to peak neurological deficit (time to
nadir) of four weeks or less [4,5]. The recovery after each
r e l a p s es h o u l db ec o m p l e t eo rn e a rc o m p l e t e[ 3 ] ,w i t ha
minimum of at least two months between relapses [12].
Patients with treatment related fluctuations [13] and
patients with the recurrent form of chronic inflammatory
demyelinating polyneuropathy (CIDP), in whom time to
nadir is more than 2 months, were excluded [14].
Ten consecutive RGBS patients (nine males and one
woman, aged 43) in remission and without immunomo-
dulatory therapy, admitted to Sahlgrenska University
Hospital during relapses, were included for follow-up
examination. All patients had been treated during attacks
with intravenous immunoglobuline or plasma exchange,
and two patients had previously received prophylactic
immunosuppressive therapy. Healthy controls were the
patients’ spouses (n = 5) or age-matched subjects (n = 5;
mean age 52, range 33-69 years). The study was approved
by the Medical Ethics Committee and written informed
consent was obtained from all participants.
Clinical examination and retrospective evaluation
A neurological follow-up examination was performed
with scoring according to Medical Research Council
s u ms c o r e( M R C )[ 1 5 ] ,a n dt h ed e g r e eo fr e m i s s i o n
(complete or incomplete) was recorded for the second
and last attack. MRC score of 60 (maximum in healthy
persons) is defined as a complete recovery. At follow-up
the patients were free from relapse. Nine patients had
not received immunomodulatory treatment for at least
one month before examination and blood sampling, and
one patient (with a history of ulcerative colitis) had
received low dose cortisone (10 mg/day) until 1 week
prior to blood sampling. The median time from the last
relapse to examination and sampling was 7 months
(range 1 month-12 years). Information of antecedent
events, number of episodes and interval between epi-
sodes, time to second episode, age at first and last epi-
sode, duration of the plateau phase, episode duration,
and the degree of remission for each episode were
obtained from medical records. Neurophysiological fol-
low-up examination including nerve conduction study
was performed according to routine methods used at
the Department of Clinical Neurophysiology at Sahl-
grenska University Hospital.
Leukocyte isolation
Peripheral leukocytes (neutrophils, monocytes, and lym-
phocytes) were isolated from heparinized venous blood
by dextran sedimentation and hypotonic lysis of remain-
ing erythrocytes as described elsewhere [16,17]. Leuko-
cytes were resuspended (10
7 cells/ml) in Krebs-Ringer
buffer (KRG) [18]. No significant differences in leuko-
cyte counts or distribution were detected between
patients and controls or between groups of patients with
different severity of RGBS (data not shown). Sorting
experiments revealed that > 99% of the oxygen radical
production in peripheral blood leukocytes was contribu-
ted by phagocytic cells, i.e. monocytes and neutrophilic
granulocytes (data not shown).
NADPH oxidase activity
Leukocyte production of superoxide anion, which is the
initial oxygen radical formed by the NADPH oxidase
[18], was assessed in duplicate using isoluminol/lumi-
nol-enhanced chemiluminescence (CL) technique [19].
The CL was measured in a Biolumat LB 9505 (Berthold
Co., Wildbad, Germany), using a 1 ml reaction mixture
containing 10
6 leukocytes, horseradish peroxidase (4 U/
ml), and isoluminol or luminol (20 μM). The cells were
activated by 10
-7 Mf M L F ,1 0
-7 MW K Y M V Mo r5×
10
-8 M PMA.
Myeloperoxidase activity
Myeloperoxidase (MPO), a leukocyte enzyme, forms
hypochlorous acid from H2O2 which results in the pro-
duction of toxic halides and the hydroxyl radical [20].
MPO activity was assessed in leukocytes (KRG, 10
7
cells/ml) and measured spectrophotometrically as the
oxidation of 4-aminoantipyrine in the presence of
hydrogen peroxide and MPO [17]. Volumes of 430 μl
2.5 mM 4-aminoantipyrine and 500 μl1 . 7m MH 2O2
were added to cuvettes. After equilibration for 4 min at
room temperature, 100 μl sonicated cells (2 × 10
6 cells/
ml), pre-incubated with 0.1% Triton X-100, were added.
The change in absorbance was measured at 510 nm for
4 min (Perkin Elmer lambda 2) in duplicate and the
mean value was used for statistical analysis.
Microbiological analyses
A standardized set of serological analyses for diagnosis
of viral and bacterial infections were performed at the
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tal. Serum IgG and IgM analyses for cytomegalovirus
(CMV), Epstein-Barr virus (EBV), herpes simplex virus
(HSV), varicella zoster virus (VZV), mumps, measles,
rubella, enterovirus, influenza A and B, parainfluenza,
respiratory syncytial virus (RSV), adenovirus and Myco-
plasma pneumoniae were performed in the acute and
convalescent phases of several RGBS attacks. The fol-
lowing methods were used: enzyme-linked immunosor-
bent assay (ELISA) for IgG and immunofluorescence
(IF) assay of IgM antibodies against HSV (type 1 and 2),
VZV and CMV; by IF assay of IgG and IgM antibodies
against EBV, mumps, measles, and Toxoplasma gondii;
by ELISA of IgM for enteroviruses, rubella, RSV and
Mycoplasma pneumoniae; and by complement fixation
(CF) assay of antibodies against influenza A and B. Cri-
teria for positive diagnosis of these infections were
either at least a four-fold titre-rise between paired sam-
ples (IgG and CF) or positive IgM at more than four-
fold dilutions over negative controls. The assay of Cam-
pylobacter jejuni infection was based on a DIG-ELISA
utilising an outer membrane glycoprotein. Criteria for
diagnosis were positive IgM or IgA titres or a significant
rise of consecutive IgG titres [21].
Statistics
Superoxide anion production and MPO activity were
analyzed as response variables with a linear model
using RGBS severity groups as predictors with a one-
sided research hypothesis based on previous findings
for GBS. The measurement day was used as a nuisance
factor to adjust for experimental day-to-day variation.
A paired test was used between patients and controls.
For numeric severity variables the relationship to
superoxide anion production was analyzed by one-
sided Pearson (r) or Spearman (rs) correlation. The
logarithm of the time to the second bout was used in
correlation analysis.
Results
Clinical data
T h em e d i a nt i m eb e t w e e nt h ef i r s ta t t a c ka n df o l l o w -
up was 15 years (0.5-40 years). A total of 38 attacks
occurred in these patients (median 3 per patient,
range 2-7) (Table 1). Five patients had complete
recovery and 5 patients had motor residual deficit at
follow-up.
Preceding infections in relation to relapse
Several relapses were preceded by an infectious illness,
most commonly by an upper respiratory tract infection
(present in 8 patients) or a Campylobacter infection
(present in 5 patients and detected in 13 of 22 episodes)
(Table 1).
Correlation between clinical aspects of RGBS and
respiratory burst
The superoxide anion production after stimulation with
fMLF and WKYMVM was significantly lower in RGBS
patients with incomplete than complete recovery after
the second attack (p = 0.0035 for both peptides) and at
follow-up (p = 0.004 and p = 0.003; Table 2 and Fig. 1).
Superoxide anion production was correlated with MRC
score at follow-up when induced by fMLF (rs =0 . 8 5 ,
p = 0.001) and by WKYMVM (rs = 0.82, p = 0.002).
Table 1 RGBS patient characteristics
Clinical data RGBS patients, n = 10
Mean number episodes per patient 3
(2-7)
Follow-up time since first episode 15 years
(0.5-40 years)
Mean age at follow-up 52 years
(33-73 years)
Mean age first episode 35.7 years
(21-52 years)
Respiratory care 3 patients,
7 episodes
Preceding infection
at relapse
URTI 8 patients,
22 episodes
Campylobacter jejuni 5 patients,
13 of 22 episodes*
CMV 3 patients,
4 of 5 episodes*
RSV 1 patient,
3 of 4 episodes*
Influenza A 1 patient,
1 of 3 episodes*
VZV reactivation 1 patient,
1 of 4 episodes*
URTI- upper respiratory tract infection
* Number of episodes with a positive virus- or Campylobacter
serology per number of episodes with adequate (according to section
Microbiological analyses) sampling and analysis.
Only positive findings were included in this table.
Table 2 Superoxide anion production in leukocytes
isolated from RGBS patients with incomplete and
complete recovery at follow- up
O2
- production (Mcpm)
stimuli - recovery + recovery p value
fMLF 47 ± 23 170 ± 25 0.004
WKYMVM 54 ± 20 166 ± 21 0.003
PMA 488 ± 35 576 ± 38 0.08
Leukocytes isolated from RGBS subjects were triggered with fMLF (10
-7 M),
WKYMVM (10
-7 M) or PMA (5 × 10
-8 M). The release of superoxide anions was
measured by isoluminol/luminol-enhanced CL. Data are presented as marginal
mean peak values ± SEM comparing O2
- production between patients with
incomplete (-) and complete (+) recovery using a one-sided test in a linear
model.
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with fMLF and WKYMVM was associated with a longer
plateau phase during relapse (r = -0.59, p = 0.037 and
r = -0.58, p = 0.04), a shorter median interval between
relapses (r = 0.68, p = 0.016 and r = 0.76, p = 0.006),
and a shorter interval to the second attack (r = 0.58, p =
0.039 and r = 0.66, p = 0.02). There was no significant
difference in superoxide anion production between
RGBS patients and their age-matched controls, for
whom the superoxide anion production was intermedi-
ate between patients with complete and incomplete
r e c o v e r y( p=0 . 0 9f o rf M L F ,p=0 . 1 9f o rW K Y M V M
and p = 0.23 for PMA).
A lower superoxide anion production after stimulation
with fMLF and WKYMVM was associated with a longer
distal motor latency (rs = -0.74, p = 0.007 and rs =- 0 . 6 9
and p = 0.015), a lower motor nerve conduction velocity
(rs = 0.59, p = 0.037 for both peptides), and a lower amplitude
(rs = 0.58, p = 0.037 and rs = 0.69, p = 0.013) at follow-up.
MPO activity
MPO activity in leukocytes did not differ between
patients and controls (p = 0.63) or between severity
groups of RGBS patients with complete or incomplete
recovery (p = 0.57) (data not shown).
Discussion
A main finding in this study was that superoxide anion
production by leukocytes in response to NADPH oxi-
dase-activating peptides was associated with severity of
disease in patients with RGBS. Thus, the superoxide
anion response to fMLF and WKYMVM was signifi-
cantly lower in RGBS patients with incomplete recovery,
higher residual motor deficit, and longer duration of the
plateau phase during attacks. We also observed a signifi-
cant association between the individual attack frequency
(shorter interval between relapses including the time
from the onset to the second relapse) and respiratory
burst, indicating a higher tendency for the disease to
recur in patients with low superoxide anion production.
The peptides fMLF and WKYMVM activates NADPH
oxidase via formyl peptide receptors (FPRs), which are
transmembrane G-protein coupled receptors present in
monocytes and neutrophils. fMLF interacts with FPR1,
whereas WKYMVM binds to FPR2 and FPR3 [22].
Notably, the severity of RGBS was unrelated to the oxygen
radical production in response to PMA, a membrane-
permeable proteine kinase C (PKC) activator [23]. PKC is
located downstream of FPR1, FPR2 and FPR3 and
upstream of the NADPH oxidase, and thus activates the
oxidase independently of FPRs. Since no difference in
MPO activity was detected, the difference in radical pro-
duction is not dependent on the H2O2 (produced by the
NADPH oxidase) consuming MPO-H2O2-halide system.
Our findings therefore suggest that the overall function of
the oxidase is intact in patients with severe RGBS, and that
the reduced responsiveness to NADPH oxidase inducers in
patients with severe RGBS is located upstream of PKC.
These findings imply that the capacity of leukocytes to
mount a respiratory burst is of relevance to the severity
of autoimmunity, as previously shown in monophasic
GBS and in MS [10,11]. In this regard GBS, RGBS and
MS mirror previous studies in rodents, in which a defi-
cient NADPH oxidase was associated with severity of
experimental autoimmunity [7-9]. The mechanisms
underlying the association between low oxygen radical
production and severe symptoms of autoimmunity dis-
ease are not known. In accordance with previous studies
[1], we found a high incidence of infections prior to
onset of RGBS, and it may be speculated that a reduced
oxygen radical production results in a less efficacious
microbial clearance. An alternative or supplementary
mechanism relates to the regulatory effects of oxygen
radicals on T cells and other subsets of lymphocytes.
Phagocyte-derived oxygen radicals efficiently trigger
apoptosis in CD4
+ and CD8
+ T cells [24,25], and it is
conceivable that a deficient elimination of autoreactive
T cells by oxygen radicals may aggravate autoimmune
manifestations [26].
Figure 1 Production of superoxide anion in leukocytes isolated
from RGBS patients in relation to complete and incomplete
remission. Leukocytes isolated from RGBS patients were stimulated
by 10
-7 M fMLF. The production of superoxide anion was measured
kinetically by isoluminol or luminol-amplified chemiluminescence.
Responses are given as Mcpm (10
6 counts per minute), presented
as the mean CL values ± SEM at different time points. The statistical
significance of difference in superoxide anion production between
subjects with complete (solid line) and incomplete recovery (dashed
line) was determined using two-tailed, unpaired Student’s t-test, p <
0.01**, p < 0.001***.
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damage of tissue in several diseases including athero-
sclerosis, reperfusion injury, and emphysema [6]. ROS
produced locally in CNS function as a mediator of
demyelination and axonal injury, both in experimental
autoimmune encephalomyelitis and MS [27,28]. How-
ever, there is increasing evidence for a protective role of
innate immunity in autoimmune disease [29] in which
oxygen radicals dampen the development of autoim-
mune disorders (reviewed in [30]). This is shown in
Crohn’s disease where a defect neutrophil function,
including migration, chemotaxis, supeoxide anion pro-
duction, and phagocytosis has been described [31]. The
effects of a deficient oxygen radical production in
chronic granulomatous disea s e( C G D )a r ei n t e r e s t i n g .
CGD is caused by an inability of the NADPH oxidase to
produce oxygen radicals and is characterized by recur-
rent infections, sterile granuloma but is also associated
with autoimmune diseases [32,33]. In a recent study,
CGD monocytes were shown to produce significantly
higher levels of cytokines than control cells [34] which
could explain the association with autoimmunity. It is
thus important to discriminate between oxygen radicals
and oxidative stress. The latest is a process of harmful
massive production of oxygen radical with tissue
destructive properties. On the other hand, oxygen radi-
cals produced at the right time and place and with strict
(redox) regulation may have a beneficial regulatory
potential, playing a crucial role in the innate immune
defence [35].
Conclusion
In conclusion, we propose that the capacity of leuko-
cytes to generate oxygen radicals in response to
NADPH oxidase-triggering peptides is related to the
severity of RGBS. The mechanistic aspects of this asso-
ciation should be the subject of further study, along
with studies outlining the role of leukocyte-derived
oxygen radical for other autoimmune diseases.
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